Vyondys 53 (golodirsen) is a prescription drug used to treat Duchenne muscular dystrophy. The drug comes as a liquid solution that’s typically given once per week by intravenous (IV) infusion. Vyondys ...
Vyondys 53 (golodirsen) is a prescription drug used to treat Duchenne muscular dystrophy. Vyondys 53 can cause side effects that range from mild to serious. Examples include headache, fever, and belly ...
The FDA has granted accelerated approval to Vyondys 53 (golodirsen; Sarepta Therapeutics) injection for the treatment of Duchenne muscular dystrophy. The Food and Drug Administration (FDA) has granted ...
Sarepta Therapeutics, Inc. SRPT announced that the FDA granted accelerated approval to Vyondys 53 (golodirsen) for the treatment of patients with Duchenne muscular dystrophy (“DMD”) who are exon 53 ...
ELK GROVE VILLAGE, Ill.--(BUSINESS WIRE)--Orsini Pharmaceutical Services (“Orsini”), a leading independent national specialty pharmacy focused on patients with rare and complicated diseases, announced ...
NEW YORK, Dec. 13, 2019 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) today celebrated the decision by the US Food and Drug Administration (FDA) to grant accelerated marketing approval to ...
Vyondys 53 (golodirsen) is a brand-name infusion that’s prescribed for Duchenne muscular dystrophy (DMD) in certain adults and children. As with other drugs, Vyondys 53 can cause side effects, such as ...
Vyondys 53 (golodirsen) is a brand-name drug that’s prescribed for Duchenne muscular dystrophy (DMD) in adults and children with a certain gene mutation. Vyondys 53 comes as an intravenous infusion ...
Golodirsen 50mg/mL; soln for IV infusion after dilution; preservative-free. Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 ...
Sarepta Therapeutics, Inc. SRPT announced that the FDA granted accelerated approval to Vyondys 53 (golodirsen) for the treatment of patients with Duchenne muscular dystrophy (“DMD”) who are exon 53 ...
Sarepta Therapeutics, Inc. SRPT announced that the FDA granted accelerated approval to Vyondys 53 (golodirsen) for the treatment of patients with Duchenne muscular dystrophy (“DMD”) who are exon 53 ...
The approval to Vyondys 53 is likely to boost total revenues for Sarepta. The company’s already approved DMD drug, Exondys 51, treats patients who are exon 51 amenable. Exondys 51 has generated sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback